The Week in Review: Cross-Border Collaboration

MDRNA, Inc. and AstraZeneca Investment (China) announced an RNAi cancer collaboration to be carried out at AstraZeneca’s Shanghai R&D center; Milestone Scientific expects SFDA approval of its dental anesthesia medical device within four months; OriGene Technologies raised $16 million to build a mAb library in China; Wuxi MTLH Biotechnology sold the China rights for its lead molecule, an anti-cancer drug, to a subsidiary of Shanghai Pharmaceutical Group; Simcere Pharma (先声药业) successfully completed a Phase IV clinical trial of Endostar in patients with non-small cell lung cancer; and while most of the ramifications of the the US Healthcare Reform are unknown, it is clear that China will continue to increase its importance to the US life science industry. More details... Stock Symbols: (NSDQ: MRNA) (OTCBB: MLSS) (NYSE: SCR)